Download Poster (303.99 KB)

Publication
  • CCR East •
  • 1 May, 2025 •
  • •

Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies

Angelo Gaffo, Herbert Baraf, Anand Patel, Tuhina Neogi, Rehan Azeem, Wesley DeHaan, Ben Peace , Hugues Santin-Janin, Bhavisha Desai, Naomi Schlesinger

Available materials

Poster Abstract
Publication
  • CCR East •
  • 1 May, 2025 •
  • •

Reduction in Tophi Observed in Patients with Chronic Refractory Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies

Herbert Baraf, Puja Khanna, Frédéric Lioté, Rehan Azeem, Wesley DeHaan, Ben Peace , Hugues Santin-Janin, Bhavisha Desai, Alan Kivitz

Available materials

Poster Abstract
Publication
  • CCR East •
  • 1 May, 2025 •
  • •

Practice Patterns and Adherence with Treatment Guidance in the Management of HLH/MAS Associated with sJIA or AOSD: Insights from a Quantitative Survey

Ingrid Pan, Ashley Teusink-Cross, Amod Athavale, Amal Gulaid, Bhagyashree Oak, Brittany Smith, Abiola Oladapo, Matthew Wojdyla, Lynes Torres Cartularo, Astrela Moore

Publication
  • ACR •
  • 28 October, 2025 •
  • •

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

Michael Marrone, Christopher McPherson, Abiola Oladapo

Publication
  • ACR •
  • 27 October, 2025 •
  • •

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Publication
  • ACR •
  • 26 October, 2025 •
  • •

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

Publication
  • PReS •
  • 19 September, 2025 •
  • •

Changes in Pharmacodynamic Markers (PD) in Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Alexi Grom, Fabrizio De Benedetti

Available materials

Oral Presentation
Sign up for alerts